TITLE

TEVA GETS FIRST FDA APPROVAL OF KETOCONAZOLE 2% CREAM

PUB. DATE
June 2000
SOURCE
Worldwide Biotech;Jun2000, Vol. 12 Issue 6, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Teva Pharmaceutical Industries Ltd. has received from the United States Food and Drug Administration an approval to manufacture and market Ketoconazole 2% Cream.
ACCESSION #
3229263

 

Related Articles

  • Teva Pharmaceuticals USA. Rankin, Ken // Drug Store News;8/18/97, Vol. 19 Issue 13, pCP16 

    Profiles Kulpsville, Pennsylvania-based generic drug company Teva Pharmaceutical Industries Ltd. Contact information; Financial performance; Company history; Business profile.

  • Teva markets some of top generics.  // Drug Store News;8/18/97, Vol. 19 Issue 13, pCP54 

    Reports on developments related to Teva Pharmaceutical Industries Ltd. Drugs marketed; Business operations in the United States; Company profile.

  • Focusing on new products, partnering.  // Drug Store News;2/16/98, Vol. 20 Issue 3, pCP12 

    Profiles Sellersville, Pennsylvania-based Teva Pharmaceuticals Industries Ltd. New product strategy by the company for 1998; Partnerships being planned by the company; Comment by Bill Fletcher, chief executive officer of the company.

  • Teva Pharmaceutical slammer dunk. Goldgaber, Arthur; Allaux, Jean-Francois // Financial World;4/15/97, Vol. 166 Issue 4, p26 

    Reports about the prospects of investing in Teva Pharmaceutical Industries, a company based in Petach Tikva, Israel. Introduction of Copaxone in the market; Anticipated increase in Teva's sales due to Copaxone and the launching of generic drugs; Confidence of Bennett Zimmerman and investors in...

  • Market briefs. Lerner, Matthew // Chemical Market Reporter;08/18/97, Vol. 252 Issue 7, p13 

    Reports that Teva Pharmaceutical Industries Ltd. has recalled five batches of clindamycin, a semi-synthetic antibiotic, after the United States Food & Drug Administration found certain deficiencies in the qualification of the raw material used to make the drugs.

  • Teva Announces Debut Of Naproxen Time-release Tablets.  // Drug Store News;10/19/98, Vol. 20 Issue 17, pCP49 

    Announces the availability of Teva Pharmaceuticals USA's Naproxen delayed-release tablets. Cost-savings alternative to the brand product.

  • FDA GRANTS 'APPROVABLE' FOR TEVA'S ANDA FOR GABAPENTIN.  // Worldwide Biotech;Sep2002, Vol. 14 Issue 9, p5 

    Deals with the approval received by Teva Pharmaceutical Industries Ltd. from the U.S. Food and Drug Administration for its generic equivalent of the anticonvulsant drug of Pfizer.

  • TEVA REPORTS ON NEUROPROTECTION PROPERTIES OF COPAXONE.  // Worldwide Biotech;Jan2003, Vol. 15 Issue 1, p7 

    Deals with the research made by Teva Pharmaceutical Industries Ltd. about the neuroprotective properties Copaxone for multiple sclerosis.

  • Full-Speed Ahead for Teva, Cephalon Deal.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p9 

    The article reports the consent order in connection with on hold acquisition of Cephalon, biopharmaceutical company, by Teva Pharmaceutical Industries Ltd., and Teva will also allow nonexclusive U.S. rights to market modafinil tablets.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics